4.6 Review

The Continuing Question of Adjuvant Therapy in Clear Cell Renal Cell Carcinoma

期刊

CANCERS
卷 14, 期 24, 页码 -

出版社

MDPI
DOI: 10.3390/cancers14246018

关键词

adjuvant therapy; renal cell carcinoma; immune checkpoint inhibitors; tyrosine kinase inhibitors

类别

向作者/读者索取更多资源

This article discusses the treatment options and methods for clear cell renal cell carcinoma after radical nephrectomy. Currently, oral vascular endothelial growth factor receptor tyrosine kinase inhibitors or intravenous immune checkpoint inhibitors are the approved treatments, although they can cause toxic reactions. Multiple clinical trials are currently underway to explore the role of adjuvant treatment after nephrectomy, and biomarkers may help determine the effectiveness of treatments for patients.
Simple Summary Treatment options after radical nephrectomy for clear cell renal cell carcinoma (ccRCC) have been studied extensively in large randomized clinical trials. Currently, two therapies are approved for patients to receive for one year: pembrolizumab or sunitinib. Newer advances are being developed to help select patients, since approved therapies can cause toxicity. The aim of our review is to discuss past and recent clinical trials that led to the current approvals and upcoming methods for ideal patient selection. Treatment advances in kidney cancer continually evolve. The focus of treatment options continues with oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) or intravenous immune checkpoint inhibitors (ICIs). Multiple trials exploring the role of adjuvant treatment after cytoreductive nephrectomy in high-risk clear cell renal cell carcinoma are currently ongoing. The discovery of biomarkers may help determine which patients benefit from these treatments, but these are not yet available outside clinical studies. Trials with combination therapies are also ongoing, especially using novel therapies with new mechanisms of action, and will hopefully provide more clues on proper patient and therapy selection in the adjuvant setting.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据